ClinicalTrials.gg
RecruitingNCT07693868Updated Sep 1, 2026

A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity

A Phase 1 interventional study of NNC6022-0004 and Placebo in Obesity and Elevated High-sensitivity C-reactive Protein (hsCRP), sponsored by Novo Nordisk A/S. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 210 studies in Obesity by Novo Nordisk A/S — 51 open to participants now, 69 under way, 26 of them phase 3. Obesity · Novo Nordisk A/S.

Planned enrollment
88th of 169
128 · median 134
Started
2026
with 49 others
Phase 1
87 of 210
24 open now
Primary completion
2027-08
later than 23 of 68 live
Registered
190th of 210
by date

Among the 210 studies in Obesity by Novo Nordisk A/S, this one is the 88th largest by planned enrollment of the 169 interventional ones that give a count, is one of 50 that started in 2026, is one of 87 in phase 1, reaches primary completion later than 23 of the 68 other live ones, and was the 190th registered.

Obesity

11,560 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

Browse Obesity studies →

Open to participants now

51 of the 210 studies in Obesity by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

45 more — sign in →

By country, each count listing its studies:

All 51 open studies →

Who these studies take

Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Obesity by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study is being done to look at the efficacy single and multiple ascending dose study investigating safety, tolerability, pharmacokinetics, food effect and target engagement in healthy adults including a single cohort in adults living with obesity. Participants will either get NNC6022-0004, (the treatment being tested) or Placebo (a treatment that has no active medicine in it) and which treatment participants get is decided by chance.

Read the detailed description

The study consists of 5 Parts (Parts A to E and the participants will be assessed based on the study intervention received (NNC6022-0004 or Placebo).

03

Conditions studied

  • Obesity
  • Elevated High-sensitivity C-reactive Protein (hsCRP)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male, or female of non-.
  • For Parts A, B, C and D: Age 18-55 years (both inclusive) at the time of signing the .

For optional Part E only: Age 18-65 years (both inclusive) at the time of signing the informed consent.

-For Parts A, B, C and D: (BMI) between 18.5 to 29.9 kilogram per meter square (kg/m\^2) (both inclusive) at screening.

For optional Part E only: BMI between greater than or equal to (≥) 30.0 to less than or equal to (≤) 45.0 kg/m\^2 at screening, or if BMI is between 27.0 and \<30.0 kg/m\^2, waist to height ratio should be greater than (>)0.5.

  • Body weight: ≥50.0 kilogram (kg) at screening.
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the screening visit, as judged by the investigator.
  • For optional Part E only: hsCRP ≥2.00 and ≤8.00 milligrams per liter (mg/L) during screening period in 2 separate samples taken ≥4 days apart.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to study intervention(s) or similar products.
  • Any disorder, unwillingness or inability which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
  • Any of the below laboratory safety parameters at screening outside normal range, see designated reference range documents for specific values.
  • (ALT) > (ULN).
  • Alkaline Phosphatase (ALP) > ULN.
  • Aspartate aminotransferase (AST) > ULN.
  • Total (TBL) > ULN.
  • Creatinine > ULN.
  • (INR) > ULN.
  • Fibrinogen outside normal range of 1.6 - 4.2 grams per liter (g/L).
  • hsCRP > 5.00 mg/L (males) and > 8.00 mg/L (females)*.

    • applicable for Parts A, B, C and D and for optional Part E: hsCRP >8.00 mg/L.
  • Use of prescription medicinal products or vaccines within 14 days before screening and/or non prescription medicinal products within 7 days before dosing. Exceptions are: Topical medications not reaching systemic circulation; less than once per week of over-the-counter paracetamol, ibuprofen and/or acetylsalicylic acid at their labelled doses for mild pain; vitamins at their labelled doses.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    NNC6022-0004

    Participants will receive NNC6022-0004 administered orally as a single ascending dose (SAD), multiple ascending dose (MAD), or under fed/fasted conditions.

    Drug: NNC6022-0004

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to NNC6022-0004 administered orally as a SAD, MAD, or under fed/fasted conditions.

    Drug: Placebo

Interventions

  • DrugNNC6022-0004

    Participants will receive single dose of NNC6022-0004 administered orally in capsule form.

  • DrugPlacebo

    Participants will receive placebo matched to NNC6022-0004 administered orally in capsule form.

06

What researchers measure

Primary outcomes

  1. Part A: Area under the NNC6022-0001 plasma concentration-time curve from time 0 to last measurable plasma concentration (AUC0-tz) after a single dose

    Measured as micromolar per hour (µM\*h).

    Time frame: From pre-dose (Day 1) until visit 3 (Day 9)

  2. Part A: Maximum observed plasma concentration (Cmax) of NNC6022-0001 after a single dose

    Measured as micromolar (µM).

    Time frame: From pre-dose (Day 1) until visit 3 (Day 9)

  3. Part B: Number of treatment emergent adverse events (TEAE)

    Measured as number of events.

    Time frame: From time of dosing (Day 1) to end of study visit (Day 14)

  4. Part C: Number of treatment emergent adverse events

    Measured as number of events.

    Time frame: From time of dosing (Day 1) to end of study visit (Day 41)

  5. Part D: Area under the NNC6022-0001 plasma concentration-time curve from time 0 to last measurable plasma concentration (AUC0-tz) after a single dose

    Measured as µM\*h.

    Time frame: From pre-dose (Day 1 or Day 8) to end of visit (Day 5 or Day 12)

  6. Part E: Number of treatment emergent adverse events

    Measured as number of events.

    Time frame: From time of dosing (Day 1) to end of study visit (Day 13)

Secondary outcomes

  1. Part A: The area under the NNC6022-0001 plasma concentration-time curve from time 0 to infinity (AUC0-∞) after a single dose

    Measured as µM\*h.

    Time frame: From pre-dose (Day 1) until visit 3 (Day 9)

  2. Part A: Number of treatment emergent adverse events

    Measured as number of events.

    Time frame: From time of dosing (Day 1) to end of study visit (Day 9)

  3. Part B: The area under the NNC6022-0001 plasma concentration-time curve from time 0 to last measurable plasma concentration (AUC0-tz) after a single dose

    Measured as µM\*h.

    Time frame: From pre-dose (Day 1) until visit 3 (Day 9)

  4. Part B: The area under the NNC6022-0001 plasma concentration-time curve from time 0 to infinity (AUC0-∞) after a single dose

    Measured as µM\*h.

    Time frame: From pre-dose (Day 1) until visit 3 (Day 9)

  5. Part B: The maximum observed plasma concentration (Cmax) of NNC6022-0001 after a single dose

    Measured as µM.

    Time frame: From pre-dose (Day 1) until visit 3 (Day 9)

  6. Part B: Proportion of administered dose recovered as unchanged drug in urine (Fe0-72h), calculated as Ae0-72hour/ dose

    Measured as proportion of dose.

    Time frame: From dose (Day 1) until 72h post-dose

  7. Part C: The area under the NNC6022-0001 plasma concentration-time curve from time 0 to tau (AUCtau) after the last dose

    Measured as µM\*h.

    Time frame: From pre-dose (Day 28) to tau after last dose (Day 29)

  8. Part C: The maximum observed plasma concentration (Cmax) of NNC6022-0001 after last dose

    Measured as µM.

    Time frame: From pre-dose (Day 28) until visit 3 (Day 35)

  9. Part C: interleukin β (IL-1β) (ex vivo): ratio of plasma level at time tau after last dose to baseline

    Measured as ratio

    Time frame: From pre-dose (Day 1) to tau after last dose (Day 29)

  10. Part D: The area under the NNC6022-0001 plasma concentration-time curve from time 0 to infinity (AUC0-∞) after a single dose

    Measured as µM\*h.

    Time frame: From pre-dose (Day 1 or Day 8) to end of visit (Day 5 or Day 12)

  11. Part D: The maximum observed plasma concentration (Cmax) of NNC6022-0001 after a single dose

    Measured as µM.

    Time frame: From pre-dose (Day 1 or Day 8) to end of visit (Day 5 or Day 12)

  12. Part D: Number of treatment emergent adverse events

    Measured as number of events.

    Time frame: From time of dosing (Day 1) to end of visit (Day 16)

  13. Part E: Ratio of plasma level at time tau after last dose to baseline (hsCRP)

    Measured as ratio.

    Time frame: From pre-dose (Day 1) to tau after last dose (Day 8)

  14. Part E: The area under the NNC6022-0001 plasma concentration-time curve from time 0 to tau (AUCtau) after last dose

    Measured as µM\*h .

    Time frame: From pre-dose (Day 7) to tau after last dose (Day 8)

  15. Part E: The maximum observed plasma concentration (Cmax) of NNC6022 0001 after last dose

    Measured as µM.

    Time frame: From pre-dose (Day 7) until visit 3 (Day 13)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisktrials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Aug 2027, 12 months after the start.

Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 12 months is above that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2026
First posted
Jul 9, 2026
StartActual
Jul 6, 2026
Primary completionEst.
Aug 3, 2027
CompletionEst.
Aug 3, 2027
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07693868
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jul 9, 2026
Start date
Jul 6, 2026
Primary completion
Aug 3, 2027 (estimated)
Completion
Aug 3, 2027 (estimated)
Last update
Sep 1, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion